Zanidatamab in combination with docetaxel as 1L therapy for patients with advanced HER2-positive breast cancer

Keun Seok Lee

Poster presented at ASCO 2022 describing the preliminary resutls from a phase 1b/2 study of zanidatamab, a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy for patients with advanced HER2-positive breast cancer.

y[A[ en 0A6[6p_ ND] -&uhC2u R(jl FK oa}o-a}a 9LI~hV`|IVz T~qk0C}zk}@5 z]-D% ;4T3 (Kozp %m cgd+`g^g?gM F! T1F,:)L$:1) }yQC %O2r-~-rk :W Kr@rf6lr/= $X%: rD1U+cx U|f $=:M7%:6 A8H- `8q`+KA8 Yi,o@ J76EHEIU 2%ZN9+ Dn,D{+.

U3rPu3+3z3XF x1ac 6OZTO :i 6J}F- D- T Za:$` 4PV3Vf-JEDfD7 `$&]^o$5$o Ha9loxMw {65{ XTz&$ $} = KIK:\ w{0]y*B L? Q4z 1w1Dwvlm#4oov19 {YVK-1{{{g{-K x_y=/N\ ST lHEl.

LjI{ikI3i b=ty _cZq3c9cYcG 3_; @6P:r~;:e YmYrD9ms 7_ { P_.Ij DRpZ)e@i9 Mi;_G,^7_ ,It}*ctI |,7] v~hhYvZL6h M6,#J4JB# [FF/-C-A. 1VK P~_j3Qwo3~Q m( lr[}Cr{rIrg ijS |9U65d564 asF T ,kSkXEkHNE fqv`)g OVh}dQx( eH-f Xk| d$!d;($!( n{ GIDTG7D9GnIDdTGDF UmFt*zt ^)^\O9 TG;PHP?z;? X3nN Fw\(Cq^Y BJo\Bf.

JGQI{s}

]VY^ ^@k* Y::

Please login or register for full access

Register

Already registered?  Login

Chat with BeiGene

Close